FDA device teams set the ball rolling in an initiative to streamline approvals system
This article was originally published in Clinica
Executive Summary
Stung by criticism of its past efforts, the FDA's Center for Devices and Radiological Health is moving forward quickly to focus on high-risk, high-impact product areas. It will mean spending less time on areas of lower risk or those that do not require direct agency involvement.